We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Electronic Device May Help Diagnose Early Bladder Cancer

By LabMedica International staff writers
Posted on 09 Aug 2019
It is estimated that bladder cancer will affect 80,470 people in the USA this year, and about 17,670 deaths are likely to result from these cases. More...
Doctors diagnose approximately half of all bladder cancers while the cancer is still in situ, while in about one-third the disease has already spread to other parts of the bladder.

Currently, the most common ways of detecting bladder cancer are cystoscopies and urine cytology tests. The former are costly, invasive, and heavily reliant on how the operator performs them, while the latter are not very effective at detecting cancer in its early stages. Additionally, cytology tests are prone to error, as they are not the best tool for telling the difference between inflammation and malignancy.

Bioengineers at the Polytechnic University of València (València, Spain) and their colleagues have developed a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. The devices are called electronic tongues, which are a voltammetric device that can "mimic" the mechanism of human taste by using pattern-information software and sensors that can detect soluble compounds.

The scientists built on previous studies that revealed metabolic differences in the urine of people who had bladder cancer. These previous studies used established metabolomic techniques, such as liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy, to look at the metabolic profiles both before and after surgery. Bladder cancer has a high relapse rate, which is why monitoring patients is particularly important. In 2012, bladder cancer "was the ninth most common malignancy worldwide, with 430,000 newly diagnosed cases.

M. Carmen Martínez Bisbal, PhD, a biochemist and co-author of the study, said, “The preliminary results of this study, with a 75% accuracy rate, indicate that the shapes of current waveforms induced in urine through pulse voltammetry could allow, with an appropriate processing of the data, for a noninvasive diagnosis in the monitoring of patients with bladder cancer.” The study was presented at the XIII International Workshop on Sensors and Molecular Recognition held July 4-5, 2019, in Valencia, Spain.

Related Links:
Polytechnic University of València


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.